Genetic testing giant Natera has launched a proprietary AI foundation model platform built on more than 250,000 tumor exomes and over a million plasma timepoints, aiming to predict which cancer patients will respond to immunotherapy before treatment starts.
Cedars-Sinai has embedded OpenEvidence's AI clinical reference platform directly inside Epic, giving physicians, nurses, and pharmacists patient-context-aware answers grounded in medical literature at the point of care.
PathAI received FDA Breakthrough Device Designation for PathAssist Derm, an AI tool aimed at dermatopathology, a specialty where diagnostic agreement between pathologists falls below 50% on the hardest skin lesion cases.
British startup C the Signs is seeking first-of-its-kind FDA De Novo clearance for an AI tool that mines existing medical records to flag cancer risk, after helping identify 75,000 cancer patients across the UK's NHS.
Artera received FDA clearance for ArteraAI Breast, a digital pathology AI tool that scores recurrence risk for HR+/HER2-negative breast cancer patients using existing biopsy images rather than a separate genomic test.
Ibex Medical Analytics won its first FDA clearance for Prostate Detect, an AI pathology tool whose validation data showed it caught prostate cancer in 13% of cases pathologists had initially missed.
Wood Mackenzie projects utilities will build only about 28% of the 1,066 gigawatts requested for AI data centers, with the rest amounting to duplicative 'phantom load' that could distort grid planning.
Abridge is expanding from an ambient AI scribe into billing and clinical trial screening, backed by an Eli Lilly equity investment and a new NVIDIA-co-developed clinical foundation model.
Artera's ArteraAI Breast, cleared by the FDA on May 6, 2026, generates a metastasis risk score directly from biopsy slides without requiring additional genomic tissue testing.
GE HealthCare completed a $2.3 billion cash acquisition of Intelerad, a Montreal imaging-software company that manages over 230 million exams a year, betting outpatient imaging data and AI distribution matter more than scanner hardware alone.